You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • AB0230 Polymorphism of cytotoxic T-lymphocyte 4 +49A/G is associated with early prescribing the biological therapy in active early rheumatoid arthritis patients (ERA PTS) refractory to the previous subcutaneous methotrexate (SC MTX) monotherapy

Article metrics

Article menu

Download PDFPDF

Abstracts Accepted for Publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0230 Polymorphism of cytotoxic T-lymphocyte 4 +49A/G is associated with early prescribing the biological therapy in active early rheumatoid arthritis patients (ERA PTS) refractory to the previous subcutaneous methotrexate (SC MTX) monotherapy
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 2017401
Jul 2017400
Aug 2017400
Sep 20172002
Oct 20172602
Nov 2017800
Dec 2017800
Jan 20181805
Feb 20181801
Mar 20181400
Apr 20182601
May 20181800
Jun 2018600
Jul 20181000
Aug 20181201
Sep 2018601
Oct 2018200
Nov 2018802
Dec 2018801
Jan 2019200
Feb 2019001
Mar 2019401
Apr 2019602
May 2019403
Jun 2019201
Jul 2019403
Aug 20191003
Oct 2019404
Nov 2019001
Mar 2020002
Apr 2020201
May 2020001
Jun 20201603
Jul 20201402
Aug 2020403
Sep 20201000
Oct 2020402
Dec 2020601
Jan 2021001
Feb 2021004
Apr 2021205
Jun 2021002
Jul 2021004
Aug 2021003
Sep 2021002
Oct 20214012
Nov 20216011
Dec 20211204
Jan 20221001
Feb 2022200
Mar 2022202
Apr 2022402
May 2022407
Jun 2022802
Jul 2022800
Aug 2022803
Sep 2022607
Oct 2022804
Nov 2022602
Dec 2022900
Jan 2023202
Feb 2023601
Mar 20231000
May 2023002
Jul 2023304
Aug 2023203
Nov 2023001
Dec 2023600
Jan 2024600
Feb 2024203
Mar 20242012
Total4500157